Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.
Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...
Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this ...
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX Duet Real-Time PCR System to support researchers in ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results